Vildagliptin: optimal control in type 2 diabetes mellitus treatment
Incretin hormones are important for normal pancreatic islet function and glucose homeostasis. Sensitivity to glucose of the α- and β-cells of the pancreas is diminished in type 2 diabetes mellitus (T2DM), leading to impaired insulin secretion, insulin resistance due to elevated glucagon levels in hy...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2015-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/7599 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850254365783228416 |
|---|---|
| author | Alexander Sergeevich Ametov |
| author_facet | Alexander Sergeevich Ametov |
| author_sort | Alexander Sergeevich Ametov |
| collection | DOAJ |
| description | Incretin hormones are important for normal pancreatic islet function and glucose homeostasis. Sensitivity to glucose of the α- and β-cells of the pancreas is diminished in type 2 diabetes mellitus (T2DM), leading to impaired insulin secretion, insulin resistance due to elevated glucagon levels in hyperglycaemia and impaired glucagon counterregulation in hypoglycaemia. In addition, T2DM is associated with increased lipotoxicity-induced insulin resistance. This article is a comprehensive review of the safety and efficacy of vildagliptin in patients with T2DM and evaluates the extra-pancreatic effects of incretin-based therapies. Clinical evidence has proven that vildagliptin effectively decreases HbA1c with a low risk of hypoglycaemia and is weight neutral. Vildagliptin also suppresses postprandial triglyceride (TG)-rich lipoprotein levels after ingestion of fat-rich meals and reduces fasting lipolysis, suggesting inhibition of fat absorption and reduced TG stores in non-fat tissues. |
| format | Article |
| id | doaj-art-2ee27128d50d4f50b47926bff32edca5 |
| institution | OA Journals |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2015-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-2ee27128d50d4f50b47926bff32edca52025-08-20T01:57:09ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782015-12-0118412512910.14341/DM75997246Vildagliptin: optimal control in type 2 diabetes mellitus treatmentAlexander Sergeevich Ametov0Russian Medical Academy of Postgraduate EducationIncretin hormones are important for normal pancreatic islet function and glucose homeostasis. Sensitivity to glucose of the α- and β-cells of the pancreas is diminished in type 2 diabetes mellitus (T2DM), leading to impaired insulin secretion, insulin resistance due to elevated glucagon levels in hyperglycaemia and impaired glucagon counterregulation in hypoglycaemia. In addition, T2DM is associated with increased lipotoxicity-induced insulin resistance. This article is a comprehensive review of the safety and efficacy of vildagliptin in patients with T2DM and evaluates the extra-pancreatic effects of incretin-based therapies. Clinical evidence has proven that vildagliptin effectively decreases HbA1c with a low risk of hypoglycaemia and is weight neutral. Vildagliptin also suppresses postprandial triglyceride (TG)-rich lipoprotein levels after ingestion of fat-rich meals and reduces fasting lipolysis, suggesting inhibition of fat absorption and reduced TG stores in non-fat tissues.https://www.dia-endojournals.ru/jour/article/view/7599diabetes mellitusglucagon-like peptide-1glucose-dependent insulinotropic polypeptideinsulin resistancevildagliptinefficacysafety |
| spellingShingle | Alexander Sergeevich Ametov Vildagliptin: optimal control in type 2 diabetes mellitus treatment Сахарный диабет diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide insulin resistance vildagliptin efficacy safety |
| title | Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_full | Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_fullStr | Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_full_unstemmed | Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_short | Vildagliptin: optimal control in type 2 diabetes mellitus treatment |
| title_sort | vildagliptin optimal control in type 2 diabetes mellitus treatment |
| topic | diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide insulin resistance vildagliptin efficacy safety |
| url | https://www.dia-endojournals.ru/jour/article/view/7599 |
| work_keys_str_mv | AT alexandersergeevichametov vildagliptinoptimalcontrolintype2diabetesmellitustreatment |